Research based pharmaceutical company of Switzerland, Novartis has introduced a drug for the treatment of IBS (Irritable Bowel Syndrome). The launch meeting of Zelmac was held at the Jamuna Resort Limited recently. All associates of Novartis Bangladesh were present there.
IBS is a common bowel disorder identified by abdominal pain/discomfort, bloating, pain etc . Zelmac is the first and only approved drug for treating these symptoms of IBS.
Zelmac alone can control multiple symptoms associated with IBS. The treatment should be continued for 1 to 3 months. Zelmac is approved in more than 30 countries inclu-ding USA, Australia, Switzerland, Canada, Brazil, Mexico and Bangladesh. Now Zelmac is widely available in chemist shops of Bangladesh.